Know Cancer

or
forgot password

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Glioma

Thank you

Trial Information

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma


Inclusion Criteria:



1. Subjects, men and women, must be between ages 18 and 75 years.

2. Subjects must have radiographic evidence on cranial magnetic resonance imaging (MRI)
of a single, contrast-enhancing unilateral supratentorial cerebral tumor (see Section
8.4).

3 Surgery is recommended within 4 weeks of the baseline MRI scan.

4. Subjects must have a Karnofsky Performance Score of 60 or higher.

5. Subjects must have signed an Institutional Review Board (IRB)-approved informed consent
prior to any non-standard of care study procedure or no later than the start of dose dense
temozolomide.

6. Subjects must have a pathological diagnosis of a high grade (IV) malignant glioma.

7. Subjects, both men and women, must be willing to avoid pregnancy for up to 2 years
after wafer implantation surgery and be counseled regarding the unknown, and potentially
harmful, risks to the embryo or fetus from participation in this study.

Exclusion Criteria:

1. Subjects who have had prior cytoreductive surgery for high-grade glioma. Subjects who
have had a diagnostic stereotactic biopsy are eligible.

2. Subjects with more than one focus of tumor or tumor crossing the midline as assessed
by coronal cranial MRI scan.

3. Concomitant significant life-threatening disease from which the subject could
reasonably be expected to die within the first 12 months of the study.

4. Known hypersensitivity reactions to temozolomide, nitrosoureas or any other
components of the GliadelĀ® wafer.

5. Prior CNS radiotherapy.

6. Subjects who have received any prior chemotherapy for this malignant glioma prior to
the baseline evaluation or subjects who are currently being treated with
chemotherapeutic agents.

7. Subjects with fewer than 100,000 platelets per mm3 or fewer than 3.500 leukocytes per
mm3.

8. Liver function tests greater than or equal to 2.5 times the upper limit of normal
(transaminases (SGOT, SGPT), total bilirubin, alkaline phosphatase).

9. Serum creatinine equal to or greater than 1.5 times the upper limit of normal, blood
urea nitrogen (BUN) equal to or greater than 2.5 times the upper limit of normal.

10. Pregnancy, or lactating females or females of childbearing potential not using
adequate contraception.

11. Participation in any other investigational protocol in the prior twelve months for
any type of malignancy.

12. Psychological, familial, sociological or geographical conditions which do not permit
adequate medical follow-up and compliance with the study protocol.

13. Inadequately controlled hypertension (blood pressure systolic > 150 mmHg or diastolic
> 100 mmHg).

14. Unstable angina or history of myocardial infarction within six months prior to
enrollment.

15. Evidence of bleeding, diathesis, or coagulopathy. Chronic full-dose anticoagulation
with warfarin is not permitted though subjects may be on low molecular weight heparin
or fondaparinux.

16. Serious non-healing wound, ulcer, or bone fracture.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and efficacy of concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide in subjects undergoing initial surgery for newly-diagnosed high grade glioma.

Outcome Time Frame:

1st five subjects at 6 months

Safety Issue:

Yes

Principal Investigator

Renato V LaRocca, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Kentuckiana Cancer Instititue

Authority:

United States: Institutional Review Board

Study ID:

KARE003

NCT ID:

NCT00660283

Start Date:

January 2009

Completion Date:

December 2010

Related Keywords:

  • Glioma
  • GBM
  • Newly
  • diagnosed
  • malignant
  • high grade
  • Glioma

Name

Location

Kentuckiana Cancer InstituteLouisville, Kentucky  40202